Healthcare / BiotechnologyMilan
$22.50
-0.50 (-2.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $38.4M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$906M
P/E
3.9x
↓EV/EBITDA
3.0x
↓ROE
61.4%
↑Gross Margin
98.3%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+136.7%
FCF CAGR
—
FCF margin
84.1%
FCF / Net income
1.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $314.3M · net income $229.7M · FCF $264.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $314.3M | $314.3M | $74.0M | $23.1M | $23.7M |
| Net Income | $229.7M | $229.7M | $45.3M | $-6.2M | $-5.4M |
| EBITDA | $264.7M | $264.7M | $44.8M | $-2.0M | $-1.2M |
| EPS | 5.70 | 5.70 | 1.12 | -0.15 | -0.13 |
| Gross Margin | 98.3% | 98.3% | 95.8% | 85.0% | 88.0% |
| Operating Margin | 82.1% | 82.1% | 51.8% | -36.0% | 3.5% |
| Net Margin | 73.1% | 73.1% | 61.2% | -26.6% | -22.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.08 | 0.13 | 0.12 |
| Current Ratio | 7.76 | 7.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $264.3M | $264.3M | $38.4M | $-10.7M | $-9.2M |
| Returns | |||||
| ROE | 61.4% | 61.4% | 32.7% | -6.8% | -5.5% |
| Valuation | |||||
| P/E | 3.95 | 3.95 | 16.43 | — | — |
| EV/EBITDA | 2.98 | 2.98 | 16.13 | — | — |
| P/B | 2.42 | 2.42 | 5.35 | 8.00 | 5.76 |
| Growth & Yield | |||||
| Revenue Growth | 324.8% | 324.8% | 219.9% | -2.5% | — |
| EPS Growth | 409.1% | 409.1% | 846.7% | -15.4% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-29.5%
EPS terminal req.
$2.00
Spread vs growth
438.6%
5Y implied EPS CAGR
-15.8%
EPS terminal req.
$2.42
Spread vs growth
424.9%
10Y implied EPS CAGR
-3.8%
EPS terminal req.
$3.89
Spread vs growth
412.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.0%
Start / end P/E
20.1x → 3.9x
EPS bridge
1.12 → 5.70
Residual
-328.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.